Haystack Oncology has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development of TriSalus' SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist. SD-101 is delivered via hepatic arterial infusion or pancreatic retrograde venous infusion in their phase 1 and 1b clinical trials using their proprietary Pressure-Enabled Drug Delivery? (PEDD?) to overcome the challenges associated with intratumoral pressure for patients diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma.

Hepatocellular carcinoma is the most common form of liver cancer. Intrahepatic cholANGiocarcinoma is cancer that occurs in the parts of the bile ducts that are within the liver. Pancreatic adenocarcinomas is the most common form of pancreatic cancer.